| On more than one occasion over the past year, recommendations have been submitted to the regulatory authority responsible for pharmaceutical pricing in Hong Kong, proposing that medicines with existing approved indications be permitted to register new indications under a special licensing arrangement. | 移植
> 移植：肝脏 | 监管合作伙伴关系
> 与监管机构合作 | 5,000 | Regional | Regularly | 115046959426 |
| On more than one occasion over the past year, recommendations have been submitted to the regulatory authority responsible for pharmaceutical pricing in Hong Kong, proposing that medicines with existing approved indications be permitted to register new indications under a special licensing arrangement. | 移植
> 移植：肝脏 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 5,000 | Regional | Regularly | 115046959426 |
| As an orphan medicinal product for a rare disease, the cost is prohibitively high. Strong representations to this effect have already been made to the Government, the HA [[醫院管理局 – Hospital Authority], and the relevant pharmaceutical manufacturers. | 稀有
> 罕见病：大多数类型 | 影响政策和立法
> 影响医疗保健政策和立法 | 100 | Regional | Rarely | 115017299676 |
| We suggested a big pharmaceutical company to reduce its selling price as it is not affordable by the patients. | 患者权益倡导
> 患者权益倡导 | 定价与可负担性倡导
> 倡导公平的药品定价 | 5,000 | Regional | Sometimes | 115004724749 |
| The dual-pricing fees are prohibitively high. | 未指定
> 未指定 | 定价与可负担性倡导
> 倡导公平的药品定价 | 1,000 | Regional | Sometimes | 115053340704 |
| We suggested a big pharmaceutical company to reduce its selling price as it is not affordable by the patients. | 患者权益倡导
> 患者权益倡导 | 定价与可负担性倡导
> 呼吁制造商降低销售价格 | 5,000 | Regional | Sometimes | 115004724749 |
| We suggested a big pharmaceutical company to reduce its selling price as it is not affordable by the patients. | 患者权益倡导
> 患者权益倡导 | 定价与可负担性倡导
> 跟踪和监控药品定价/药品短缺 | 5,000 | Regional | Sometimes | 115004724749 |
| On more than one occasion over the past year, recommendations have been submitted to the regulatory authority responsible for pharmaceutical pricing in Hong Kong, proposing that medicines with existing approved indications be permitted to register new indications under a special licensing arrangement. | 移植
> 移植：肝脏 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 5,000 | Regional | Regularly | 115046959426 |
| We have addressed the issue of treatment options to the health authority. | 视觉障碍
> 视网膜疾病 | 改善访问路径
> 促进公平获取药品/医疗保健 | 1,000 | Local | Sometimes | 119068473108 |
| The cost of rare disease medicines classified as orphan drugs is extremely high. | 稀有
> 罕见病：大多数类型 | 改善访问路径
> 改善罕见/超罕见疗法的获取途径 | 100 | Regional | Rarely | 115017299676 |
| As an orphan medicinal product for a rare disease, the cost is prohibitively high. Strong representations to this effect have already been made to the Government, the HA [[醫院管理局 – Hospital Authority], and the relevant pharmaceutical manufacturers. | 稀有
> 罕见病：大多数类型 | 改善访问路径
> 改善罕见/超罕见疗法的获取途径 | 100 | Regional | Rarely | 115017299676 |
| The pricing of so-called 'orphan drugs' — medications designated for the treatment of rare diseases — is prohibitively expensive. | 神经系统
> 神经纤维瘤病（NF） | 改善访问路径
> 改善罕见/超罕见疗法的获取途径 | 100 | Regional | Rarely | 115018622259 |
互动
行动与倡导
